Sabesp ADR Logo
US20441A1025

Sabesp ADR

Ins Portfolio

Kurse werden geladen...

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Dividenden-Strategie 3 / 15
HGI-Strategie 8 / 18
Levermann-Strategie 4 / 13
Powered by aktien.guide

News

  • Foto von Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
    27.08. - 14:00 Uhr

    Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

    New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan's Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO. » Mehr auf accesswire.com

  • Foto von Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
    19.08. - 14:00 Uhr

    Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

    New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Hong Kong's Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO. » Mehr auf accesswire.com

  • Foto von Here's Why Momentum in Sabesp (SBS) Should Keep going
    19.08. - 13:50 Uhr

    Here's Why Momentum in Sabesp (SBS) Should Keep going

    If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. » Mehr auf zacks.com

Dividenden

Alle Kennzahlen
In 2024 hat Sabesp ADR bereits 0,26 Dividende ausgeschüttet. Die letzte Dividende wurde im Juli gezahlt.

Unternehmenszahlen

Im letzten Quartal hatte Sabesp ADR einen Umsatz von 1,12 Mrd und ein Nettoeinkommen von 201,43 Mio
(EUR) Juni 2024
YOY
Umsatz 1,12 Mrd 4,50%
Bruttoeinkommen 471,50 Mio 26,83%
Nettoeinkommen 201,43 Mio 41,61%
EBITDA 497,87 Mio 77,44%

Fundamentaldaten

Metrik Wert
Marktkapitalisierung
10,79 Mrd
Anzahl Aktien
683,51 Mio
52 Wochen-Hoch/Tief
16,50 - 10,15
Dividendenrendite
1,65 %
Dividenden TTM
0,26
Beta
0,53
KGV (PE Ratio)
16,19
KGWV (PEG Ratio)
1,72
KBV (PB Ratio)
2,07
KUV (PS Ratio)
2,43

Unternehmensprofil

Die Companhia de Saneamento Básico do Estado de São Paulo - SABESP erbringt Wasser- und Abwasserdienstleistungen für private, gewerbliche, industrielle und staatliche Kunden. Das Unternehmen erbringt Dienstleistungen in den Bereichen Wasserversorgung, Abwasserentsorgung, Regenwasserbewirtschaftung und -ableitung, Stadtreinigung und Abfallentsorgung sowie damit verbundene Tätigkeiten, einschließlich Planung, Betrieb, Wartung und Vermarktung von Energie. Zum 31. Dezember 2021 versorgte das Unternehmen ca. 27,8 Millionen Menschen mit 9,8 Millionen Wasseranschlüssen, ca. 24,6 Millionen Menschen mit 8,4 Millionen Abwasseranschlüssen und betrieb 88.904 Kilometer Wasser- und Wassertransportleitungen sowie 61.122 Kilometer Kanalisationsleitungen. Darüber hinaus bietet das Unternehmen über Zweckgesellschaften Wasser- und/oder Abwasserdienstleistungen für vier weitere Gemeinden an. Das Unternehmen wurde 1954 gegründet und hat seinen Hauptsitz in São Paulo, Brasilien.

Name
Sabesp ADR
CEO
Andre Gustavo Salcedo Teixeira Mendes
Sitz São Paulo, sp
Brasilien
Website
Industrie
Wasserversorgungsunternehmen
Börsengang
10.05.2002
Mitarbeiter 10.158

Ticker Symbole

Börse Symbol
NYSE
SBS
Frankfurt
SAJA.F
München
SAJA.MU
Düsseldorf
SAJA.DU
🍪

Parqet nutzt Cookies. Erfahre Mehr